

PuriCore Named to Deloitte's Fast 50 Program for Greater Philadelphia

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 4 November, 2008 — [PuriCore](#) plc (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, has been named to Deloitte's prestigious Fast 50 Program for Greater Philadelphia, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte LLP, one of the national's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2003 to 2007. PuriCore grew 96% in this period.

Thousands of supermarkets in more than 25 chains, including two of the top-five, and a quarter of UK hospitals use PuriCore's products to protect against the spread of infectious pathogens. From simply salt, water, and electricity, the Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing pathogens including major public health threats of MRSA, E.coli, avian flu, and salmonella.

PuriCore recently announced Q3 2008 sales of \$8.4 million, an increase of 120% (see [Interim Management Statement](#)). PuriCore also raised recently £8.4 million (\$16.6 million) in equity and \$9.7 million in debt.

[Greg Bosch](#), CEO of PuriCore, said:

"We are very proud to be named as one of Deloitte's Technology Fast 50. We have experienced significant revenue growth by focusing on our core businesses of controlling the spread of infectious pathogens in food safety and medical applications with our green technology."

R. Terry Hisey, Vice Chairman, Life Sciences, Deloitte LP, said:

"Sustaining high revenue growth over five years is an exceptional accomplishment. We commend PuriCore for making the commitment to life sciences technologies and delivering on the promise of market longevity. We are proud to name PuriCore to Deloitte's Fast 50."

About PuriCore

[PuriCore](#) plc (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobacter pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Contacts:

Jennifer Guinan
Sage Strategic Marketing
610.410.8111
jennifer@sagstrat.com

Greg Bosch, CEO
Darren Weiss, VP Finance
PuriCore
484.321.2700